In a landmark analysis that could reshape geriatric medicine, researchers have confirmed that semaglutide—the powerhouse pharmaceutical behind the global phenomena Wegovy and Ozempic—is both effective and manageable for patients over the age of 65. For years, clinicians have hesitated to prescribe aggressive weight-loss interventions to the elderly, fearing that the physiological strain of rapid weight reduction might exacerbate frailty or trigger adverse health events. However, a comprehensive new study pooling data from the STEP clinical trial program suggests that the benefits of the drug significantly outweigh the risks for this demographic.
Led by Professor Luca Busetto of the University of Padova, the research team synthesized data from six major STEP trials (1, 3, 4, 5, 8, and 9) to isolate the impact of 2.4 mg weekly semaglutide injections on adults aged 65 and older. The findings, which demonstrate consistent efficacy across weight reduction and cardiometabolic markers, offer a compelling argument for the expanded use of GLP-1 receptor agonists in an aging population that is increasingly burdened by obesity-related morbidity.
The Main Facts: Bridging the Geriatric Gap
The core of the study centered on a critical, often-overlooked demographic: adults aged 65 and older who live with obesity but do not suffer from diabetes. By excluding diabetic patients, researchers were able to cleanly evaluate the drug’s impact on weight and cardiometabolic health without the confounding variables associated with glycemic management.
The analysis involved 452 participants aged 65 and older, drawn from a larger cohort of 4,523 individuals. Of these, 248 received the 2.4 mg semaglutide dose, while 110 received a placebo. All participants underwent lifestyle interventions, including diet and exercise counseling, ensuring that the pharmacological impact could be assessed in the context of standard-of-care behavioral support.
The primary takeaway is clear: semaglutide is highly effective in older adults, mirroring the robust results previously observed in younger cohorts. Participants in the treatment group saw an average weight loss of 15.4% over 68 weeks, dwarfing the 5.1% reduction seen in the placebo group. Beyond the scale, the clinical significance of these results—measured through waist circumference reduction, improved body mass index (BMI), and superior cardiometabolic profiles—suggests that semaglutide could be a vital tool in preventing disability in the aging population.
Chronology of the Clinical Investigation
The journey to these findings was paved by the rigorous architecture of the STEP (Semaglutide Treatment Effect in People with obesity) program.
- Trial Selection: Researchers systematically combed through trials 1, 3, 4, 5, 8, and 9. These trials were chosen specifically to provide a broad range of data points, including trials that focused on intensive behavioral therapy (STEP 3) and long-term maintenance (STEP 4).
- The 68-Week Benchmark: The standard observational window for these trials was 68 weeks. This duration allowed researchers to observe not just initial weight loss, but the stabilization of cardiometabolic markers over more than a year of treatment.
- Patient Screening: Participants were required to have a BMI of at least 30 kg/m², or a BMI of 27 kg/m² combined with at least one weight-related complication, such as hypertension or dyslipidemia.
- Ongoing Monitoring: Throughout the 68-week period, clinical investigators tracked body composition, waist-to-height ratios, blood pressure, and hs-CRP (a marker of inflammation), alongside comprehensive safety monitoring for adverse events.
Supporting Data: A Statistical Deep Dive
The efficacy of semaglutide in this study was not merely statistically significant; it was clinically transformative. The data highlights a stark divergence between those receiving the medication and those in the control group.
Weight Loss Milestones
The capacity to reach specific, life-altering weight loss targets was markedly higher among the semaglutide cohort:
- 10% Weight Loss: 66.5% of the semaglutide group reached this milestone, compared to just 15.5% of the placebo group.
- 15% Weight Loss: 46.8% of the treatment group succeeded, versus 6.4% in the placebo group.
- 20% Weight Loss: Nearly 30% (28.6%) of those on semaglutide achieved this high-threshold goal, a figure that stood in stark contrast to the 2.7% observed in the control group.
Cardiometabolic and Anthropometric Improvements
Weight loss was accompanied by significant improvements in body composition metrics. Waist circumference, a key indicator of visceral fat (the dangerous fat surrounding organs), dropped by an average of 14.3 cm in the semaglutide group, more than double the reduction observed in the placebo group (6.0 cm).
Furthermore, the "healthy weight" threshold—defined as a BMI of less than 27 kg/m²—was achieved by 27% of semaglutide users, compared to only 5.5% of the placebo group. These figures indicate a successful migration of participants out of high-risk obesity classes into more sustainable, lower-risk BMI categories. Significant improvements were also noted in HbA1c levels, blood pressure, and lipid profiles, all of which contribute to a reduced risk of cardiovascular events.
Official Responses and Safety Considerations
While the efficacy data is overwhelmingly positive, the study also provided a transparent look at the safety profile. In the geriatric population, safety is paramount due to the higher baseline risk of adverse events.
Adverse Events (AEs)
The study reported that 89.1% of semaglutide participants and 84.5% of placebo participants experienced at least one adverse event. While the overall incidence of AEs was similar, researchers noted that serious adverse events were reported more frequently in the semaglutide group (19.0%) compared to the placebo group (12.7%).
Professor Busetto and his colleagues were quick to contextualize these figures. They noted that common side effects, such as constipation and dizziness, were consistent with the established side-effect profile of GLP-1 receptor agonists. Crucially, rates of more concerning issues, such as bone fractures and hypoglycemia, remained low (less than 1% in both groups), suggesting that the medication does not inherently threaten bone density or glucose stability in older adults when managed correctly.
"The safety and efficacy profile of semaglutide was consistent with that reported in the STEP program," Dr. Busetto stated. This consistency is the vital component that clinicians need to move forward with confidence in prescribing these medications to elderly patients.
Implications: A New Era for Geriatric Care
The implications of this research are profound. In many high-income countries, the prevalence of excess weight is highest among those aged 65 and older. This demographic shift has created a "silver tsunami" of age-related complications linked to obesity, including mobility issues, cardiovascular disease, and reduced quality of life.
Addressing the Quality of Life
Obesity in older adults is a primary driver of disability. By successfully reducing body weight and improving cardiometabolic markers, semaglutide has the potential to help elderly patients maintain their independence for longer. The ability to lower blood pressure and improve blood sugar control without the need for additional polypharmacy is an attractive prospect for geriatricians looking to simplify patient regimens.
A Call for Clinical Nuance
However, the study also serves as a reminder that medication is not a panacea. The success of the trial was bolstered by lifestyle interventions. As the medical community adopts semaglutide for older patients, the emphasis must remain on a holistic approach—integrating pharmacological support with nutritional guidance and physical therapy to preserve muscle mass, which is a critical concern for this age group.
Looking Toward the Future
The research team’s conclusion is clear: the fear surrounding the use of GLP-1 agonists in the elderly may be largely unfounded when patients are properly screened and monitored. As we move forward, we can expect to see updated clinical guidelines that may explicitly include older adults as candidates for semaglutide therapy.
This research does not just represent a victory for a pharmaceutical product; it represents a victory for the aging population. It offers a path to reducing the burden of disease, enhancing physical function, and ultimately, allowing older adults to age with greater vitality and health. The "STEP" program has provided the data; now, the medical community must provide the care.
